Kidney Toxicity

Kidney Toxicity, or nephrotoxicity, describes adverse effects of drugs or chemicals on renal structure or function, potentially causing acute kidney injury, chronic damage, electrolyte imbalance, or impaired filtration. Nephrotoxicity may result from direct tubular injury, immune-mediated inflammation, crystal deposition, or haemodynamic changes reducing renal perfusion.

The pharmaceutical industry monitors kidney toxicity throughout development, as renal injury represents a common cause of drug attrition and post-marketing safety concerns. Preclinical studies assess renal histopathology, biomarkers such as creatinine and urea, and emerging translational markers like KIM-1 and NGAL enabling earlier injury detection. Clinical trials monitor renal function and implement risk mitigation strategies for vulnerable populations. Certain drug classes including aminoglycosides and some anticancer agents carry known nephrotoxicity risks requiring careful dosing and monitoring. As biomarker science advances and human-relevant preclinical models improve, earlier detection and better mechanistic understanding improve nephrotoxicity risk management across development and clinical use.